HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
1 clinical trials · Condition
◉ Watch HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
| Record | Firm | Date |
|---|---|---|
| Expanded Access to Tipifarnib (NCT04809233) | Kura Oncology, Inc. |
Track HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) automatically
Every clearance here is in the API, with alerts when new ones post.